<DOC>
	<DOCNO>NCT00010270</DOCNO>
	<brief_summary>RATIONALE : LMB-9 immunotoxin locate tumor cell kill without harm normal cell . This may effective treatment advance pancreatic , esophageal , stomach , colon rectal cancer . PURPOSE : Phase I trial study effectiveness LMB-9 immunotoxin treat patient advanced pancreatic , esophageal , stomach , colon , rectal cancer .</brief_summary>
	<brief_title>LMB-9 Immunotoxin Treating Patients With Advanced Pancreatic , Esophageal , Stomach , Colon , Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity LMB-9 immunotoxin patient advance adenocarcinoma colon , rectum , pancreas , esophagus , stomach overexpression Lewis-Y antigen . - Determine maximum tolerate dose drug patient . - Determine clinical response patient treated drug . - Determine pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients receive LMB-9 immunotoxin IV continuously day 1-5 . Patients stable respond disease completion first course receive additional course every 4-5 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos LMB-9 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 3 week every 2 month thereafter . PROJECTED ACCRUAL : A total 40-50 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced adenocarcinoma colon , rectum , pancreas , esophagus , stomach refractory standard treatment Overexpression LewisY antigen Measurable evaluable disease No CNS metastasis Metastatic liver disease primary tumor allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : Platelet count great 100,000/mm^3 Absolute granulocyte count great 1,200/mm^3 Hepatic : Bilirubin normal SGOT SGPT great 1.5 time upper limit normal Hepatitis B C antigen negative No liver disease ( e.g. , alcohol liver disease ) Albumin least 3.0 g/dL Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 60 mL/min Proteinuria great 1 g/24 hour ( grade II toxicitylike ) Cardiovascular : No prior coronary artery disease No New York Heart Association class II , III , IV congestive heart failure No arrhythmia require treatment Pulmonary : FEV_1 FVC great 65 % predict Other : No concurrent malignancy No active peptic ulcer disease No known allergy omeprazole No known seizure disorder No concurrent medical psychiatric condition would preclude study participation No contraindication pressor therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : At least 3 week since prior hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>